Apraglutide
Sponsors
VectivBio AG
Conditions
Chronic Kidney DiseaseGVHDHealthy SubjectsHepatic ImpairmentSBS Associated With Intestinal Failure (SBS-IF)Short Bowel SyndromeShort Bowel Syndrome (SBS)short bowel syndrome
Phase 1
Study of Pharmacokinetics and Safety of Apraglutide in Participants With Normal and Impaired Kidney Function.
CompletedNCT04699032
Start: 2020-12-08End: 2021-07-05Updated: 2024-10-26
A Phase 1 Open-Label Evaluation of the Pharmacokinetics and Safety of a Single Dose of Apraglutide in Subjects With Normal and Impaired Hepatic Function
CompletedNCT05706623
Start: 2023-01-30End: 2023-04-04Updated: 2025-07-10
Evaluation of Apraglutide on Gastric Emptying
CompletedNCT05995704
Start: 2023-03-02End: 2023-07-24Updated: 2024-10-24
Relative Bioavailability of a New Presentation of Apraglutide Versus the Reference Formulation
CompletedNCT06002555
Start: 2023-05-23End: 2023-09-22Updated: 2024-10-26
Phase 2
Metabolic Balance Study of Apraglutide in Patients With Short Bowel Syndrome, Intestinal Failure (SBS-IF) and Colon-in-Continuity (CIC)
CompletedNCT04964986
Start: 2021-06-14End: 2023-06-06Updated: 2025-06-18
Proof-of-concept Trial of Apraglutide in Acute Graft Versus Host Disease (aGVHD)
TerminatedNCT05415410
Start: 2022-05-25End: 2024-12-17Updated: 2025-10-20
Phase 3
Trial to Evaluate Efficacy and Safety of Apraglutide in SBS-IF
CompletedNCT04627025
Start: 2021-01-26End: 2024-02-22Updated: 2024-11-27
Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome.
Active, not recruitingNCT05018286
Start: 2021-07-13End: 2027-10-30Updated: 2025-07-02
An Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome. (STARS extend)
Active, not recruitingCTIS2023-510389-28-00
Start: 2021-06-14Target: 101Updated: 2025-11-07
A Study to Investigate the Efficacy and Safety of Apraglutide Compared With Placebo in Adult Participants With Short Bowel Syndrome Associated With Intestinal Failure (SBS-IF)
RecruitingNCT07742735
Start: 2026-08-01End: 2029-10-01Target: 124Updated: 2026-08-04